



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Molecular

Collected: 08/25/2023 12:03 Received: 08/25/2023 12:03

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Rows include p210 Result, p210 %IS, p210 MR, p190 Result, p190 % Ratio, and BCR-ABL1 Comment.

The e13a2, e14a2 for the p210 product were not detected.
The e1a2 transcript for the p190 product were not detected.
The test does not monitor other rare fusion transcripts resulting from t(9;22). This test is not intended for the diagnosis of CML.

This test was performed using the QuantideX® qPCR BCR-ABL IS Kit (Assuragen) and, if negative, reflexed to the QuantideX® qPCR BCR-ABL minor Kit (Assuragen). Both kits are reverse transcription-quantitative PCR performed on the Applied Biosystems 7500 Fast Dx Real-Time OCR Instrument and is intended to measure BCR-ABL1 to ABL1. The QuantideX® qPCR BCR-ABL IS kit (major) is an in vitro nucleic acid amplification test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive Chronic Myeloid Leukemia (CML) patients expressing BCR-ABL1 fusion transcripts type e13a2 and/or e14a2. BCR-ABL1 to ABL1 is expressed as a log molecular reduction (MR value) from a baseline of 100% on the International Scale, in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs).

The QuantideX® qPCR BCR-ABL minor Kit is an in vitro nucleic acid amplification test for the quantitation of BCRABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive Chronic Myeloid Leukemia (CML) patients expressing BCR-ABL1 fusion transcript type e1a2. BCR-ABL1 to ABL1 is expressed as a percent ratio (BCR-ABL1 to ABL1) in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs).

Performing Site:

WMRL: WARDE MEDICAL LABORATORY 300 West Textile Road Ann Arbor MI 48108

Reported Date: 2023.08.25 12:03 BCRX

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F225000011
WX0000003827
Printed D&T: 08/25/23 12:03

Ordered By: KAJAL SITWALA, MD, PhD
WX00000000002365

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 1 OF 1